Angelica gigas Nakai for Health & Longevity

Evidence Review created on 05/02/2026 using AI4L / Opus 4.7

Also known as: Korean Angelica, Korean Dang-gui, Cham-Dang-Gui, Giant Angelica, Purple Parsnip, Chamdanggui, AGN

Motivation

Angelica gigas Nakai (Korean Dang-gui) is a perennial herb native to Korea and Northeast China, used in Korean traditional medicine for centuries as a “blood tonic” for anemia, women’s health, and pain. Unlike the more familiar Chinese dong quai (Angelica sinensis), the Korean species concentrates a distinct pair of pyranocoumarins — decursin and decursinol angelate — that drive most of its modern research interest, particularly around metabolic health and pain modulation.

Western interest grew through dietary supplements marketed for memory and joint comfort, and through proprietary blends targeting menopausal symptoms. Penn State investigators are running early-stage trials of a standardized extract in men with rising prostate cancer markers, while Korean groups have published trials in elevated blood fats, urinary symptoms, and menopausal complaints.

This review examines what the available preclinical and clinical evidence shows about Angelica gigas Nakai across its main proposed uses, evaluates safety and interaction signals, and outlines what remains uncertain. It surveys the active phytochemistry, the human pharmacokinetic data, and the practical considerations that bear on use in a longevity-oriented context.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Angelica gigas

The Grokipedia article provides a botanical and ethnopharmacological overview, including taxonomy (Apiaceae family, described by Nakai in 1917), traditional Korean medicinal use as cham-dang-gui, and the key pyranocoumarins decursin and decursinol angelate.

Examine

No dedicated Examine.com article exists for Angelica gigas Nakai as of May 2026.

ConsumerLab

No dedicated ConsumerLab article exists for Angelica gigas Nakai as of May 2026.

Systematic Reviews

This section presents the systematic reviews and meta-analyses identified on PubMed that bear on Angelica gigas Nakai.

Herbal therapeutics for female infertility: A systematic review and meta-analysis - Hyun et al., 2024

Meta-analysis of 18 RCTs (randomized controlled trials, the gold-standard study design that randomly assigns participants to treatment or control to test cause-and-effect) of 2,662 participants of herbal medicines for female infertility; Angelica gigas Nakai (Danggui) was identified as the second most-used single herb across qualifying formulations, with herbal therapy associated with a significant increase in pregnancy rates versus placebo.

A dedicated PubMed search on “Angelica gigas AND (systematic review OR meta-analysis)” returned only one qualifying systematic review/meta-analysis as of May 2026. Most aggregate publications on this herb are narrative reviews rather than systematic reviews.

Mechanism of Action

Angelica gigas Nakai exerts its biological activity primarily through pyranocoumarins concentrated in the root: decursin and its isomer decursinol angelate, both of which are rapidly hydrolyzed in the human gastrointestinal tract and liver to the parent metabolite decursinol. The furanocoumarin nodakenin and various polysaccharides and polyacetylenes contribute additional activity.

The proposed mechanisms span several pathways:

Cholinergic system — Decursinol inhibits acetylcholinesterase (the enzyme that breaks down the neurotransmitter acetylcholine), elevating synaptic acetylcholine in a manner mechanistically similar to medications used in dementia.
NF-κB pathway — Decursin and decursinol angelate suppress NF-κB signaling, downregulating COX-2 (cyclooxygenase-2, the inducible inflammatory enzyme), TNF-α (tumor necrosis factor alpha), and several interleukins.
AMPK and YAP signaling — A. gigas extract activates AMP-activated protein kinase (AMPK, a cellular energy sensor) and modulates Yes-associated protein (YAP, a growth/survival regulator), supporting antioxidant and metabolic effects.
VEGF/angiogenesis — Decursin and decursinol angelate inhibit VEGFR-2 (vascular endothelial growth factor receptor 2) signaling, the basis for proposed anti-tumor and vascular activity.
Hormone receptors — Decursin and decursinol angelate act as antagonists/degraders of androgen and estrogen receptors, while decursinol shows agonist activity at the estrogen receptor — a polypharmacology that complicates the simple “phytoestrogen” label.
Neurotransmitter modulation — The compounds promote glutamic acid decarboxylase (GAD, the enzyme that synthesizes the inhibitory neurotransmitter GABA) and the inhibitory GABAergic axis (gamma-aminobutyric acid, the brain’s principal inhibitory neurotransmitter), inhibit monoamine oxidase A (MAO-A, the enzyme that breaks down serotonin, dopamine, and norepinephrine), and antagonize TRPV1 (a pain-sensing ion channel), accounting for sedative, mood, and analgesic activity.
ROCK1/2 inhibition — Recently identified inhibitory activity of decursinol angelate and decursinol on Rho-associated protein kinases (ROCK1/2) provides a mechanism for vascular and oncologic effects.

Competing mechanistic interpretations exist. Many in vitro findings used decursin and decursinol angelate concentrations that human plasma never achieves; in humans, decursinol predominates 1,000-fold over decursin, so cell-culture data using the parent compounds may misrepresent the active human pharmacology. The Penn State group (which conducts AGN (Angelica gigas Nakai) clinical research with the standardized extract INM176 supplied by Nutragen Co. — a manufacturer-investigator relationship that constitutes a financial conflict of interest) has argued that the polypharmacology of decursinol — not decursin per se — drives clinical effects.

Pharmacological properties. Following oral dosing of an Angelica gigas dietary supplement (Cogni.Q, providing 119 mg decursin and 77 mg decursinol angelate) in 20 healthy adults, the terminal half-life of decursin and decursinol angelate was 17–19 hours; the half-life of decursinol was 7.4 hours. Time to peak concentration was 2–3 hours. Decursin and decursinol angelate are extensively converted to decursinol via first-pass hepatic metabolism. The principal CYP isoforms involved are CYP3A4 (a major drug-metabolizing liver enzyme that processes a large share of orally administered medications) and CYP2C19 (a liver enzyme with pronounced inter-individual genetic variability that metabolizes acid-suppressing drugs and certain antidepressants). Decursin/decursinol angelate are also weak inhibitors of CYP2A6 (a minor liver enzyme that metabolizes nicotine and a small subset of drugs). In terms of target selectivity, the pyranocoumarins are best characterized as polypharmacologic rather than highly selective: at clinically relevant decursinol concentrations they engage acetylcholinesterase, monoamine oxidase A, ROCK1/2, TRPV1, and hormone receptors at overlapping potencies. Tissue distribution of decursinol after oral dosing favors highly perfused organs including liver, kidney, and brain in rodents; lipophilicity supports central nervous system penetration, consistent with cognitive and analgesic effects observed in animal models.

Historical Context & Evolution

Angelica gigas Nakai was formally described by the Japanese botanist Takenoshin Nakai in 1917, but its medicinal use in Korea predates that by centuries. Under the name cham-dang-gui (참당귀, “true dang-gui”), the dried root has been a staple of Korean traditional medicine for treating anemia, dysmenorrhea (painful menstrual periods), postpartum complications, articular rheumatism, pain, and circulatory complaints. It is one of three Asian Angelica species used as “Dang-gui” — the others being A. sinensis (Chinese dong quai) and A. acutiloba (Japanese tōki) — but is chemically distinct in being rich in pyranocoumarins (decursin and decursinol angelate) that are absent from the Chinese and Japanese species.

The transition from traditional decoction to modern phytopharmaceutical began in the 1980s–1990s as Korean groups isolated and characterized decursin and decursinol angelate. Initial pharmacological work focused on analgesic, anti-inflammatory, and sedative properties — supporting traditional pain and tonic indications. By the early 2000s, in vitro and rodent studies extended the catalog to include anticancer, neuroprotective, and metabolic activities.

A pivotal evolution came with human pharmacokinetic work. Earlier rodent and in vitro studies treated decursin and decursinol angelate as the active species. Pharmacokinetic studies by Lü and colleagues (2012, 2015) demonstrated extensive first-pass conversion to decursinol in both rodents and humans, with decursinol reaching plasma concentrations roughly 1,000-fold higher than the parent compounds. This reframed mechanistic interpretation: many cell-culture findings using parent-compound concentrations were not physiologically relevant. The 2025 Penn State review (Lü et al.) identifies new molecular targets (ROCK1/2, GDH (glutamate dehydrogenase, an enzyme regulating glutamate and amino-acid metabolism), MAO-A, TRPV1, hormone receptors) consistent with the polypharmacology of decursinol.

The current scientific picture is in flux. A standardized extract (INM176) is in Phase I/II trials at Penn State for prostate-specific antigen (PSA, a blood marker that tracks prostate cancer activity) interception (NCT06600698, started May 2025), and Korean groups continue to publish RCTs on triglycerides, urinary symptoms, and menopausal complaints. The herb’s standing as a longevity-relevant intervention remains preliminary, with the strongest human evidence concentrated in narrow indications (triglycerides, menopausal symptoms within proprietary blends) rather than in broad health-span outcomes.

Expected Benefits

A dedicated literature search across PubMed, ClinicalTrials.gov, and review databases was performed to map the complete benefit profile of Angelica gigas Nakai.

Medium 🟩 🟩

Triglyceride Reduction

A 12-week randomized, double-blind, placebo-controlled trial in 100 Korean adults with mildly elevated fasting triglycerides (130–200 mg/dL) showed that 1 g/day of Angelica gigas Nakai extract (containing 200 mg/day of standardized AGN extract) significantly reduced triglycerides, very-low-density lipoprotein cholesterol (VLDL-C), and the TG/HDL-C ratio (triglyceride-to-HDL cholesterol, a measure of atherogenic dyslipidemia) versus placebo, with no safety signals (Jung et al., Nutrients, 2020). Mechanism involves AMPK activation and modulation of hepatic lipogenesis observed in db/db diabetic mouse models.

Magnitude: In the AGN group, mean fasting triglycerides decreased from approximately 162 mg/dL to 132 mg/dL (≈18% reduction) at 12 weeks, with statistically significant differences from placebo for triglycerides, VLDL-C, and the TG/HDL-C ratio.

Menopausal Symptom Relief (Proprietary Combination)

A 12-week randomized, double-blind, placebo-controlled trial of EstroG-100 — a proprietary herbal blend containing standardized Angelica gigas, Cynanchum wilfordii, and Phlomis umbrosa extracts — in 64 pre-, peri-, and postmenopausal women showed significant improvement in the Kupperman Menopause Index (KMI) and vaginal dryness scores versus placebo (Chang et al., Phytotherapy Research, 2012). Symptoms responding included hot flashes, paresthesia (tingling or pins-and-needles sensation), insomnia, nervousness, melancholia, vertigo, fatigue, and rheumatic pain. The European Food Safety Authority (EFSA) issued a positive safety opinion on EstroG-100 as a novel food in 2017. Angelica gigas alone has not been tested in an RCT for menopausal symptoms; the evidence is for the combination, in which it is one of three botanicals.

Magnitude: Mean KMI score in the EstroG-100 group fell from 29.5 ± 7.4 at baseline to 11.3 ± 5.8 at week 12 (≈62% reduction), versus 29.2 → 23.7 (≈19% reduction) in placebo (p < 0.01; p, the probability that the observed difference is due to chance).

Low 🟩

Cognitive Support and Memory

In animal models of mild cognitive impairment (scopolamine-induced amnesia, Aβ1-42 protein injection, traumatic brain injury, and chronic mild stress), Angelica gigas extract (notably the standardized INM-176 ethanolic extract) improved performance on passive avoidance, Morris water maze, and fear-memory tasks. The mechanism involves acetylcholinesterase inhibition by decursinol, neuroprotection of cholinergic neurons, and reduction of neuroinflammation. A small open-label Korean study in elderly subjects with cognitive impairment reported improved Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) scores after 12 weeks of INM-176, but the study is not robustly published in indexed peer-reviewed form. No large, placebo-controlled human cognitive RCTs have been completed.

Magnitude: Not quantified in available studies.

Lower Urinary Tract Symptom Improvement (Combination)

A 12-week randomized, double-blind, placebo-controlled trial of SHPro (a combination of Angelica gigas and Astragalus membranaceus) in 84 men with benign prostatic hyperplasia symptoms showed significant improvement in International Prostate Symptom Score (IPSS) total score and incomplete-emptying subscore, plus improvements in International Index of Erectile Function (IIEF) measures, versus placebo (Lee et al., Investigative and Clinical Urology, 2025). As with EstroG-100, the trial tested a combination, not Angelica gigas alone.

Magnitude: Statistically significant improvement in IPSS total (p = 0.0219) and incomplete emptying subscore (p = 0.0007); absolute IPSS point changes were modest.

Pain Modulation

Animal studies and traditional use both support analgesic activity, attributed to central nervous system modulation (serotonin/noradrenalin signaling), MAO-A inhibition, TRPV1 antagonism, and NF-κB suppression. Angelica gigas extract is sold in Korea as one of the leading herbal pain products. Human controlled pain trials remain limited; most efficacy claims in the consumer market rely on animal pharmacology and traditional use rather than RCTs.

Magnitude: Not quantified in available studies.

Speculative 🟨

Prostate Cancer Interception

In TRAMP (transgenic adenocarcinoma of mouse prostate) models, Angelica gigas root ethanolic extract dose-dependently reduced prostate carcinogenesis, with multi-omic profiling implicating immune and anti-inflammatory mechanisms. A pilot crossover trial in healthy men (NCT03630328) using 800 mg/day of the AGN supplement Cogni.Q showed safety but no significant change in select inflammatory cytokines. A Phase I/II trial (NCT06600698, Penn State) in men with rising PSA after primary treatment is currently recruiting; at 400–1,600 mg/day of INM176, the trial aims to determine the recommended Phase II dose and assess PSA stabilization. No human efficacy data yet exist.

Glycemic and Metabolic Support

In db/db diabetic mice, A. gigas extract reduced hyperglycemia and hepatic steatosis (fatty liver, the abnormal accumulation of fat in liver cells) via AMPK activation. A small Korean human trial (NCT03258229) was conducted but full results have not been widely published. Human evidence is preliminary.

Anti-Wrinkle / Skin

A small clinical study in 22 women evaluated Angelica gigas root extract prepared with mineral-rich water for facial wrinkle parameters; the formulation was associated with measurable improvement (Kang et al., Journal of Cosmetic Dermatology, 2023). The study was not a robust RCT and used a topical/cosmetic preparation rather than oral supplementation.

Mood, Sleep, and Anxiety

Decursin/decursinol angelate promote GABAergic inhibitory tone and inhibit MAO-A, providing a mechanistic basis for anxiolytic and sleep-modulating effects observed in rodents. Human clinical evidence is anecdotal and absent from the controlled-trial literature.

Benefit-Modifying Factors

CYP3A4 / CYP2C19 metabolism status: Decursin and decursinol angelate are converted to decursinol primarily by CYP3A4 and CYP2C19. Carriers of poor-metabolizer alleles for CYP2C19 (common in East Asian populations, ~15–20%) may have altered decursinol exposure. The Penn State Phase I/II trial (NCT06600698) explicitly stratifies pharmacokinetic outcomes by CYP2C19 and CYP3A4 metabolizer status.
Baseline triglyceride level: The triglyceride-lowering RCT enrolled adults with fasting triglycerides 130–200 mg/dL. Benefit may be greater in those at the upper end of this range and minimal in normolipidemic individuals.
Sex differences in absorption: In the human pharmacokinetic study (Zhang et al., 2015), men absorbed decursin and decursinol angelate faster and reached peak decursinol concentrations more quickly than women, though total area under the curve (AUC) was similar.
Pre-existing hepatic or renal impairment: Because decursinol formation depends on hepatic first-pass metabolism, patients with significant liver impairment may have altered exposure; renal impairment may slow elimination of decursinol metabolites.
Menopausal status: Estrogen-receptor activity of decursinol (agonist) and decursin/decursinol angelate (antagonist/degrader) suggests symptomatic benefits in menopausal women may be greater, but theoretical risks in hormone-sensitive conditions also rise (see Risks).
Age: Cholinergic decline is age-related, so any acetylcholinesterase-inhibitory benefit on cognition would be expected to be more relevant in older adults; no age-stratified human cognitive trials have been conducted.

Potential Risks & Side Effects

A dedicated literature search across drug-reference sources (drugs.com), pharmacovigilance literature, and clinical trial reports was performed to map the side-effect profile of Angelica gigas Nakai.

Low 🟥

Mild Gastrointestinal Symptoms

Across published clinical trials of Angelica gigas extract or Angelica gigas-containing combinations (triglyceride RCT, EstroG-100 RCT, SHPro lower urinary tract symptoms RCT, AGN immune pilot), the most commonly reported adverse events have been mild gastrointestinal complaints (nausea, diarrhea, abdominal discomfort), usually self-limited and not requiring discontinuation.

Magnitude: Incidence reported as low (single digits per cent) and similar to placebo in published RCTs.

Headache, Dizziness

Reported in supplement reviews and case-level data as occasional adverse experiences. The mechanism may involve GABAergic and MAO-A modulation. No case has been reported as serious.

Magnitude: Not quantified in available studies.

Speculative 🟨

Hormone-Sensitive Condition Risk

Decursin and decursinol angelate exhibit estrogen receptor antagonist/degrader activity, while decursinol shows agonist activity. The polypharmacology has not been characterized in clinically relevant doses or in humans with hormone-sensitive conditions. By precedent with other phytoestrogens, caution is conventionally advised for women with estrogen-receptor-positive breast cancer or endometrial pathology, and for men with hormone-sensitive prostate cancer not in the clinical trial setting.

Bleeding Risk (Theoretical)

Coumarins from Angelica species have shown anti-platelet activity in laboratory studies; some compounds were 2–4 times more inhibitory than aspirin in platelet aggregation assays. Although Angelica gigas pyranocoumarins are not the warfarin-like vitamin K antagonists, the Penn State Phase I/II trial excludes patients on warfarin, reflecting precautionary concern. No clinical bleeding events have been reported in published trials.

Hepatic Effects

The pilot trial of AGN supplement Cogni.Q at 800 mg/day did not demonstrate hepatic injury markers in healthy men. Subchronic toxicity studies in rats (13-week) found no significant adverse effects across hepatic, renal, and hematologic parameters. However, because decursinol formation depends on hepatic CYP metabolism, theoretical hepatic strain at high doses or in those with pre-existing hepatic disease has not been excluded.

Pregnancy / Lactation

No controlled safety data exist for pregnancy or breastfeeding. Traditional Korean medicine has used A. gigas during pregnancy in some preparations, but the modern literature uniformly advises against use during pregnancy and lactation, given pharmacologic activity on hormone receptors and lack of controlled data.

Photosensitivity

Furanocoumarins (e.g., nodakenin) in Angelica species can theoretically cause phototoxicity. Angelica gigas contains lower furanocoumarin levels than some other Angelica species, and clinical photosensitivity has not been reported in trials, but the theoretical risk is conventionally noted.

Risk-Modifying Factors

CYP2C19 / CYP3A4 polymorphisms: Poor metabolizer status may alter exposure to decursin/decursinol angelate (slower conversion to decursinol), with unclear net effect on adverse events.
Baseline biomarker levels: Baseline elevations in liver enzymes (ALT/AST — alanine aminotransferase and aspartate aminotransferase, the two main enzymes used to gauge liver-cell injury), reduced platelet count (< 150 × 10⁹/L), or impaired renal function (eGFR — estimated glomerular filtration rate, a calculated measure of how well the kidneys clear waste from the blood — < 60 mL/min/1.73 m²) increase the risk profile, since hepatic first-pass metabolism, anti-platelet activity, and metabolite clearance are all biomarker-sensitive. Pre-treatment laboratory values therefore meaningfully modulate adverse-event likelihood.
Baseline hormone status: Hormone-sensitive cancers (estrogen-receptor-positive breast cancer, endometrial cancer, hormone-sensitive prostate cancer outside a trial setting) represent a conventionally cautioned population given the herb’s hormone-receptor activity.
Sex differences: No clinically meaningful sex-specific adverse event signal has been reported, though pharmacokinetic absorption differs (faster in men).
Pre-existing conditions: Bleeding disorders (theoretical), significant liver disease (alters decursinol formation), and hormone-sensitive malignancies are conventionally cautioned.
Age: No age-specific adverse signal has been demonstrated; older adults on multiple CYP3A4-metabolized medications may be at higher risk for drug interactions.

Key Interactions & Contraindications

Anticoagulants and antiplatelet agents (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, aspirin): Theoretical additive bleeding risk based on coumarin chemistry and in vitro anti-platelet activity. Severity: caution; the Penn State Phase I/II trial explicitly excludes patients on warfarin/coumadin. Mitigation: avoid concurrent use unless coagulation status is closely monitored.
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice) and inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): May alter conversion of decursin/decursinol angelate to decursinol and thereby modulate exposure. Severity: monitor; the Penn State trial requires evaluation for potential drug interactions in subjects taking strong CYP3A4 inhibitors/inducers. Mitigation: discuss timing and dose with a pharmacist if combination is unavoidable.
Strong CYP2C19 inhibitors (omeprazole, esomeprazole, fluconazole, fluvoxamine): May alter pyranocoumarin metabolism. Severity: monitor. Mitigation: consider alternative acid-suppressing therapy if long-term combination is anticipated.
Hormonal therapies (tamoxifen, aromatase inhibitors, oral contraceptives, hormone replacement therapy, androgen deprivation therapy): Theoretical interaction via estrogen and androgen receptor activity. Severity: caution. Mitigation: avoid in patients on antiestrogen or androgen deprivation therapy outside a clinical trial setting.
Sedatives, hypnotics, alcohol: Possible additive central nervous system depression via GABAergic activity and MAO-A inhibition. Severity: caution. Mitigation: avoid concurrent high-dose alcohol or polypharmacy.
Other supplements with anti-platelet activity (high-dose fish oil, Ginkgo biloba, garlic, ginger, curcumin): Possible additive bleeding risk including increased bruising or prolonged bleeding time. Severity: caution. Mitigation: avoid stacking multiple anti-platelet supplements; if combination is unavoidable, monitor for unusual bleeding or bruising and discontinue 7–14 days before any planned procedure.
Other AGN-containing products: Stacking multiple supplements containing A. gigas extract (e.g., Cogni.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula) leads to unintended cumulative dose and over-exposure to decursin/decursinol angelate. Severity: caution. Mitigation: use only one AGN-containing product at a time; the Penn State trial requires a 4-week washout from any AGN-containing product before enrollment.
Populations who should avoid the intervention:
- Pregnant or breastfeeding women
- Men with hormone-sensitive prostate cancer outside a clinical trial setting (e.g., on active androgen deprivation therapy)
- Women with estrogen-receptor-positive breast cancer or endometrial pathology
- Patients on warfarin or with significant bleeding disorders (e.g., platelet count < 100 × 10⁹/L)
- Patients with severe hepatic impairment (e.g., Child-Pugh Class C)
- Patients with severe renal impairment (e.g., eGFR < 30 mL/min/1.73 m²)
- Children (no safety data)
- Patients undergoing surgery (recommended discontinuation 1–2 weeks prior)

Risk Mitigation Strategies

Start with a low dose: Begin at the lower end of the manufacturer’s labeled dose (typically 400 mg/day of standardized extract) and increase only if tolerated, to identify any idiosyncratic gastrointestinal or central nervous system effects early.
Discontinue 1–2 weeks before surgery: To mitigate theoretical bleeding risk from coumarin-related anti-platelet activity, stop the supplement 7–14 days before any planned procedure with bleeding risk.
Avoid stacking AGN-containing products: Use only one A. gigas-containing supplement at a time to prevent unintended dose accumulation; follow the Penn State trial precedent of a 4-week washout when switching products.
Monitor liver enzymes during prolonged high-dose use: Although clinical trials have not demonstrated hepatotoxicity, baseline and 12-week ALT/AST monitoring is reasonable for users at doses ≥ 800 mg/day of standardized extract for more than 12 weeks, particularly in those with pre-existing hepatic risk factors.
Coordinate with prescribers when on CYP3A4/CYP2C19 substrates with narrow therapeutic indices: Examples include certain anti-arrhythmics, some immunosuppressants, certain anticonvulsants, and some chemotherapeutic agents; consult a pharmacist if uncertain.
Avoid concurrent anticoagulants without medical supervision: Patients on warfarin, direct oral anticoagulants, or dual antiplatelet therapy should not initiate A. gigas without explicit physician approval and INR/coagulation monitoring.
Avoid in pregnancy, lactation, and hormone-sensitive disease: Hard contraindication; do not use without specialist medical guidance.

Therapeutic Protocol

The therapeutic protocol below summarizes how Angelica gigas Nakai is used in the supplement market and in published clinical trials. There is no single “standard of care” protocol; usage varies substantially across products and indications.

Standard dose ranges: Across published RCTs and pharmacokinetic studies, total daily doses of 400–1,600 mg of standardized A. gigas root ethanolic extract have been tested. The Cogni.Q product delivers 800 mg/day (split: 400 mg twice daily), providing approximately 119 mg decursin and 77 mg decursinol angelate. The triglyceride RCT used 1 g/day of A. gigas Nakai extract preparation (containing 200 mg/day standardized AGN extract). The Penn State Phase I/II trial escalates from 400 mg/day to 1,600 mg/day of INM176 powder.
Competing approaches: No single dominant therapeutic approach exists. The traditional Korean approach uses water decoctions of dried root (often 6–12 g/day in formulae), while modern Western supplement use favors standardized ethanolic extracts in capsules. The combination-product approach (EstroG-100 for menopausal symptoms; SHPro for lower urinary tract symptoms; multi-herb cancer formulae such as SH003) is a third pattern, supported in those specific indications by RCTs.
Best time of day: No empirically established optimal timing. The 17–19 hour terminal half-life of decursin/decursinol angelate allows once-daily or split-dose schedules. For sleep-supportive use (a traditional indication), evening dosing is conventionally preferred.
Half-life: Decursin terminal half-life ≈17.4 hours; decursinol angelate ≈19.3 hours; decursinol ≈7.4 hours in healthy adults.
Single dose vs. split dose: Both regimens appear in clinical trials. The Cogni.Q product label and the Penn State trial protocol use split doses (twice daily) at higher daily totals; the 12-week triglyceride RCT used once-daily 1 g dosing. Split dosing may smooth peak-trough variation but is not empirically required.
Genetic polymorphisms relevant to dosing: CYP2C19 and CYP3A4 metabolizer status affects decursinol exposure. CYP2C19 poor metabolizers (≈15–20% of East Asian populations, ≈2–5% of European populations) may have higher decursin/decursinol angelate exposure relative to decursinol; the clinical significance is not yet established.
Sex-based differences: Men reach peak decursinol concentrations faster than women; the total exposure (AUC) is similar. No sex-specific dose adjustment is established.
Age-related considerations: Older adults metabolize CYP3A4 substrates more slowly on average; conservative dose initiation (400 mg/day) is reasonable in adults over 65.
Baseline biomarker considerations: The triglyceride RCT excluded subjects with normal triglycerides; benefit appears more likely in those with mildly elevated baseline triglycerides (130–200 mg/dL).
Pre-existing conditions: Patients with significant hepatic impairment may have altered first-pass metabolism; renal impairment may slow elimination of decursinol metabolites. No formal dose adjustment recommendations exist.

Discontinuation & Cycling

Lifelong vs. short-term: Angelica gigas Nakai is not established as a lifelong intervention. Most clinical trials have used 12-week to 6-month courses. The longest published human safety data come from the Phase I prostate cancer interception program, which is studying continuous daily dosing across multiple 28-day cycles.
Withdrawal effects: No withdrawal syndrome has been reported. The herb does not have known dependence-producing properties.
Tapering protocol: No tapering is required for discontinuation based on available evidence.
Cycling for efficacy: No evidence supports cycling of A. gigas for sustained efficacy. The 4-week washout requirement in the Penn State trial reflects pharmacokinetic clearance, not a clinical “drug holiday” recommendation.

Sourcing and Quality

Standardized extract preferred: Choose products labeled with a specific decursin and/or decursinol angelate content (e.g., Decursinol-50 standardized to a defined decursin level; Cogni.Q standardized to provide 119 mg decursin and 77 mg decursinol angelate per daily dose). Avoid raw root powder products that lack content standardization.
Third-party testing: Look for products certified by third-party testers such as USP (United States Pharmacopeia), NSF International, ConsumerLab, or Informed Choice. Angelica gigas products are not commonly included in major US third-party testing programs at this time.
Reputable brands and clinical-grade products: INM176 (Nutragen Co., Korea) is the standardized extract used in the Penn State Phase I/II trial. Cogni.Q (Quality of Life Labs) is the product used in the published human pharmacokinetic study. EstroG-100 (Naturalendo Tech) is the EFSA-approved combination product for menopausal symptoms. Life Extension’s “Fast-Acting Joint Formula” includes a Korean angelica extract standardized to decursinol. Note: each of these manufacturers (Nutragen Co., Quality of Life Labs, Naturalendo Tech, Life Extension) has a direct financial interest in the published evidence supporting its product, and most of the corresponding clinical research is conducted by investigators with sponsor-supplier relationships — readers should weigh this conflict of interest when interpreting brand-specific clinical claims.
Country of origin and species verification: Korean-cultivated A. gigas root is the traditional and scientifically studied source. Verify the species is Angelica gigas Nakai and not A. sinensis (Chinese dong quai), A. acutiloba (Japanese tōki), or A. archangelica; these contain different bioactive profiles and are not interchangeable.
Organic / pesticide testing: Root crops can accumulate soil contaminants; preference should go to organically grown and heavy-metal-tested products.

Practical Considerations

Time to effect: In the triglyceride RCT, statistically significant biomarker change required 12 weeks. In the EstroG-100 menopausal trial, symptomatic improvement was measured at 12 weeks with progression apparent by 4 weeks. For pain and cognitive support, no robust human time-to-effect data exist. A reasonable practical expectation is a 4–12 week trial period before judging response.
Common pitfalls: Confusing Angelica gigas Nakai with Angelica sinensis (dong quai) or Angelica archangelica — the species are chemically distinct. Using non-standardized root powder products with unverifiable potency. Stacking multiple AGN-containing supplements unintentionally (e.g., a separate joint formula plus a separate cognitive formula). Combining with anticoagulants without medical guidance.
Regulatory status: In the United States, Angelica gigas extracts are sold as dietary supplements under DSHEA (the Dietary Supplement Health and Education Act of 1994, the federal law that defines and regulates dietary supplements); they are not FDA-approved as drugs. EstroG-100 holds a positive EFSA novel food safety opinion (2017) for the European market. INM176 is in FDA-regulated Phase I/II clinical investigation.
Cost and accessibility: Standardized extract products are available through major US online supplement retailers. Cost ranges from approximately USD 0.50–1.50 per daily dose, depending on standardization and brand. The herb is widely available in Korea and East Asian markets at lower cost as raw root or basic extract.

Interaction with Foundational Habits

Sleep: Angelica gigas may have a sedative effect via GABAergic potentiation and MAO-A inhibition (mechanism); its traditional use includes sedative indications. Direct interaction: potentiating effect on sleep is plausible but not demonstrated in controlled human sleep studies. Practical consideration: evening dosing may be preferred for those finding mild sedation; avoid combination with alcohol or sedatives.
Nutrition: Direct interaction: decursin/decursinol angelate absorption may be enhanced by food (fat-containing meals support absorption of lipophilic coumarins), based on compound chemistry; no formal food-effect study has been published. Practical consideration: take with a meal containing some fat for consistent absorption. Grapefruit juice and other strong CYP3A4 inhibitors should be avoided due to interaction with first-pass metabolism. The herb does not deplete known nutrients.
Exercise: Direct interaction: none well-characterized. The compounds do not blunt resistance training adaptations as has been raised for high-dose antioxidants. Practical consideration: no timing requirement around workouts. Theoretical anti-inflammatory activity may complement recovery without blunting hypertrophy (muscle-growth) signaling, but this has not been directly studied in athletes.
Stress management: Direct interaction: indirect, via GABAergic potentiation and MAO-A inhibition (mood/anxiety mechanism). Practical consideration: not a substitute for established stress-management practices (sleep, mindfulness, exercise); may complement them in those with mild mood symptoms, though no controlled human anxiety trials have been completed.

Monitoring Protocol & Defining Success

Baseline testing helps establish hepatic and renal function and a personal benchmark before initiating Angelica gigas Nakai, particularly when planned use exceeds 12 weeks or doses exceed 800 mg/day of standardized extract.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT (alanine aminotransferase)	< 25 U/L (men), < 20 U/L (women)	Hepatic safety baseline given CYP-mediated metabolism	Conventional reference: < 40 U/L. Fasting preferred.
AST (aspartate aminotransferase)	< 25 U/L	Hepatic safety baseline	Conventional reference: < 40 U/L.
eGFR (estimated glomerular filtration rate)	> 90 mL/min/1.73 m²	Renal clearance baseline; metabolite elimination	Cystatin C-based eGFR more accurate in older adults and athletes.
CBC with platelet count	Platelets 150–400 × 10⁹/L	Bleeding-risk baseline given theoretical anti-platelet activity	CBC = complete blood count, a panel measuring red cells, white cells, and platelets. Standard reference range applies.
Fasting triglycerides	50–100 mg/dL	Tracks the best-evidenced metabolic benefit	Conventional reference: < 150 mg/dL; functional optimum lower. 12-hour fast required.
TG/HDL-C ratio (triglycerides over high-density lipoprotein cholesterol)	< 2.0	Tracks cardiometabolic response	Functional marker of insulin resistance and atherogenic dyslipidemia.
PSA (prostate-specific antigen, men ≥ 40 y)	Trend more important than absolute value	Relevant for men using AGN for prostate cancer interception	Conventional reference: < 4 ng/mL; functional approach emphasizes PSA velocity and density. Annual or per-trial schedule.
Coagulation panel (PT/INR)	INR 0.8–1.2 (off anticoagulants)	Bleeding-risk monitoring if combined with anti-platelet/anticoagulant context	PT/INR = prothrombin time / international normalized ratio, a measure of blood-clotting speed. Only required if combining with relevant medications.
Total testosterone (men)	600–900 ng/dL	Hormone-receptor pharmacology baseline	Morning fasting draw. Free testosterone if SHBG (sex hormone-binding globulin, the main blood protein that binds and transports sex hormones) abnormal.
Estradiol (premenopausal women)	Cycle-phase dependent	Hormone-receptor pharmacology baseline	Day 3 of cycle for follicular phase reference.

Ongoing monitoring cadence: repeat ALT/AST/eGFR/CBC at 12 weeks after initiation, then every 6–12 months for continued use. Repeat lipid panel at 12 weeks if using for triglyceride benefit. PSA monitoring per existing prostate cancer surveillance schedule for men using AGN in that context.

Qualitative markers worth tracking subjectively:

Sleep quality and ease of falling asleep
Joint comfort and morning stiffness (if used for pain)
Hot flash frequency and severity (if used for menopausal symptoms)
Cognitive clarity, working memory, and concentration
Energy level and exercise recovery
Mood and stress resilience

Emerging Research

Phase I/II trial of INM176 in prostate cancer interception (NCT06600698): Open-label dose-escalation Phase I/II at Penn State Cancer Institute, started May 2025, estimated enrollment 45 men with rising PSA after primary treatment. Doses 400–1,600 mg/day of INM176 powder. Primary outcomes: maximum tolerated dose, recommended Phase II dose, and PSA stabilization/reduction over six 28-day cycles. Pharmacokinetics stratified by CYP2C19 and CYP3A4 metabolizer status.
AGN-CognI.Q Phase I in prostate cancer (NCT05375539): Completed Phase I dose-response and acute pharmacokinetic study (n=12) in prostate cancer patients of the Cogni.Q AGN supplement.
Pilot trial of AGN supplement in healthy men (NCT03630328): Completed crossover pilot (n=15) showed no impairment of hepatic or renal function and no significant cytokine modulation at the labeled dose; supports safety baseline for the dose-escalation Phase I/II.
Lower urinary tract symptoms RCT (SHPro): Lee et al., 2025 reported significant IPSS and IIEF improvement in men with benign prostatic hyperplasia symptoms over 12 weeks with the A. gigas + Astragalus membranaceus combination, supporting further investigation in male urinary health.
Comprehensive update on AGN bioactivities: Lü et al., 2025 reviews emerging molecular targets including ROCK1/2 inhibition, MAO-A inhibition, TRPV1 antagonism, and GAD/GABA promotion that reframe mechanistic understanding of decursinol as the principal active human metabolite.
Could weaken the case: Adequately powered Phase II follow-on to the current Penn State NCT06600698 trial that fails to demonstrate PSA stabilization would substantially reduce enthusiasm for prostate-cancer interception. Negative replication of the Jung et al., 2020 triglyceride RCT in non-Korean populations would similarly limit generalizability.
Could strengthen the case: Successful Phase II/III prostate-cancer interception data following the Lü et al., 2025 framework, plus well-designed cognitive RCTs informed by Sowndhararajan & Kim, 2017, would substantially elevate the herb’s clinical standing. Confirmation of safe long-term use (>1 year) would extend its applicability.
Mechanistic unknowns: The hormone-receptor polypharmacology (decursinol agonist; decursin/decursinol angelate antagonist) reviewed in Lü et al., 2025 needs human characterization to clarify net effects on hormone-sensitive tissues. Decursinol-specific clinical pharmacology, distinct from parent compounds, deserves dedicated study.

Conclusion

Angelica gigas Nakai (Korean Dang-gui) is a centuries-old Korean medicinal root whose modern interest centers on the plant compounds decursin and decursinol angelate, extensively converted in the human body to decursinol. The most consistent human evidence supports modest triglyceride-lowering at twelve weeks and symptomatic relief of menopausal complaints in proprietary combinations. Animal and mechanistic data point to broader cognitive, analgesic, anti-inflammatory, and oncologic effects with weaker human support. A current early-stage trial in men with rising prostate cancer markers represents the leading active human investigation.

Safety appears favorable in published trials, with mild gastrointestinal symptoms the most common reported events. Theoretical concerns include bleeding risk, hormone-receptor activity in hormone-sensitive conditions, and liver-enzyme-mediated drug interactions; pregnancy and concurrent warfarin use are conventional contraindications. Research has been carried out predominantly by Korean academic groups and a small number of US investigators, with active commercial interests in standardized extracts; this conflict of interest is a salient feature of the published clinical literature. The herb sits in a category where promising mechanism and traditional use are accompanied by limited controlled human outcome data.

Top - Benefits - Risks - Protocol

Angelica gigas Nakai for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Medium 🟩 🟩

Triglyceride Reduction

Menopausal Symptom Relief (Proprietary Combination)

Low 🟩

Cognitive Support and Memory

Lower Urinary Tract Symptom Improvement (Combination)

Pain Modulation

Speculative 🟨

Prostate Cancer Interception

Glycemic and Metabolic Support

Anti-Wrinkle / Skin

Mood, Sleep, and Anxiety

Benefit-Modifying Factors

Potential Risks & Side Effects

Low 🟥

Mild Gastrointestinal Symptoms

Headache, Dizziness

Speculative 🟨

Hormone-Sensitive Condition Risk

Bleeding Risk (Theoretical)

Hepatic Effects

Pregnancy / Lactation

Photosensitivity

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion